Structure-Based Virtual Screening Accelerates GPCR Drug Discovery

  • Trends Pharmacol Sci. 2020 Jun;41(6):382-384. doi: 10.1016/j.tips.2020.04.001.
Lei Liu  1 ,  Ralf Jockers  2
Affiliations
  • 1. Cellular Signaling Laboratory, International Research Center for Sensory Biology and Technology of MOST, Key Laboratory of Molecular Biophysics of Ministry of Education, School of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China; Université de Paris, Institut Cochin, CNRS, INSERM, F-75014 Paris, France.
  • 2. Université de Paris, Institut Cochin, CNRS, INSERM, F-75014 Paris, France. Electronic address: [email protected].
PMID: 32340753 DOI: 10.1016/j.tips.2020.04.001
Abstract

Virtual ligand screening (VLS) against high-resolution structures of G-protein-coupled receptors (GPCRs) is likely to become the next-generation drug design approach of choice. Stein and colleagues recently demonstrated the feasibility of such an approach by discovering novel chemical scaffolds for the melatonin MT1 receptor and compounds with unique in vivo activities.

Keywords
G-protein-coupled receptor; circadian rhythm; melatonin; melatonin receptor.